Hoogeveen E K, Kostense P J, Eysink P E, Polak B C, Beks P J, Jakobs C, Dekker J M, Nijpels G, Heine R J, Bouter L M, Stehouwer C D
Institute for Research in Extramural Medicine, Vrije Universiteit, Van der Boechorststraat 7, 1081 BT Amsterdam, the Netherlands.
Arch Intern Med. 2000 Oct 23;160(19):2984-90. doi: 10.1001/archinte.160.19.2984.
Retinopathy is the leading cause of blindness among patients with type 2 diabetes mellitus (DM). Hyperhomocysteinemia is a recently recognized risk factor for cardiovascular disease, independent of established risk factors.
To study the association between the homocysteine level and retinopathy among subjects with and without DM.
We studied an age-, sex-, and glucose tolerance-stratified random sample of a 50- to 75-year-old general white population in the Hoorn Study (N = 625). Retinal vascular changes (retinopathy) were assessed using ophthalmoscopy and/or fundus photography. Hyperhomocysteinemia was defined as a serum total homocysteine level greater than 16 micromol/L.
The prevalence of retinopathy was 9.8% (28/285) in subjects with normal glucose tolerance, 11.8% (20/169) in those with impaired glucose tolerance, 9.4% (10/106) in those with newly diagnosed type 2 DM, and 32.3% (21/65) in those with known type 2 DM. The prevalence of retinopathy was 10.3% (39/380) in subjects without hypertension and 16.3% (40/245) in subjects with hypertension; it was 12.0% (64/534) in subjects with a serum total homocysteine level of 16 micromol/L or less and 16.5% (15/91) in those with a serum total homocysteine level of more than 16 micromol/L. After stratification for DM and adjustment for age, sex, glycosylated hemoglobin, and hypertension, the odds ratio (95% confidence interval) for the relation between retinopathy and hyperhomocysteinemia was 0.97 (95% confidence interval, 0.42-2.82) in patients without DM and 3.44 (95% confidence interval, 1.13-10.42) in patients with DM (P =.08 for interaction).
The findings suggest that hyperhomocysteinemia may be a risk factor for retinopathy in patients with type 2 DM, but probably not in patients without DM. Arch Intern Med. 2000;160:2984-2990
视网膜病变是2型糖尿病(DM)患者失明的主要原因。高同型半胱氨酸血症是一种最近被认识到的心血管疾病风险因素,独立于已确定的风险因素。
研究有无DM的受试者中同型半胱氨酸水平与视网膜病变之间的关联。
我们在Hoorn研究中对50至75岁普通白人人群按年龄、性别和糖耐量进行分层随机抽样(N = 625)。使用检眼镜检查和/或眼底摄影评估视网膜血管变化(视网膜病变)。高同型半胱氨酸血症定义为血清总同型半胱氨酸水平大于16微摩尔/升。
糖耐量正常的受试者中视网膜病变患病率为9.8%(28/285),糖耐量受损者中为11.8%(20/169),新诊断的2型DM患者中为9.4%(10/106),已知2型DM患者中为32.3%(21/65)。无高血压受试者中视网膜病变患病率为10.3%(39/380),有高血压受试者中为16.3%(40/245);血清总同型半胱氨酸水平为16微摩尔/升或更低的受试者中为12.0%(64/534),血清总同型半胱氨酸水平大于16微摩尔/升的受试者中为16.5%(15/91)。在对DM进行分层并对年龄、性别、糖化血红蛋白和高血压进行校正后,无DM患者中视网膜病变与高同型半胱氨酸血症之间关系的比值比(95%置信区间)为0.97(95%置信区间,0.42 - 2.82),有DM患者中为3.44(95%置信区间,1.13 - 10.42)(交互作用P = 0.08)。
研究结果表明,高同型半胱氨酸血症可能是2型DM患者视网膜病变的一个风险因素,但可能不是无DM患者视网膜病变的风险因素。《内科学文献》。2000年;160:2984 - 2990